SUBSCRIBE
SUBSCRIBE

Merck & Co.

AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
NEWS
Policy
McKesson Corporation Can be Sued for Distributing Merck & Co., Inc.'s NuvaRing
June 25, 2012
 · 
1 min read
Pharm Country
Mystery Sounds From a Merck & Co., Inc. Plant? No One Knows
June 19, 2012
 · 
1 min read
Biotech Bay
Here Is How We Know Merck & Co., Inc.'s Gardasil Has Not Killed 100 People
May 4, 2012
 · 
1 min read
Pharm Country
Merck & Co., Inc. Flushing Drug May Tackle Baldness
March 22, 2012
 · 
1 min read
Biotech Bay
Merck & Co., Inc. Chemists Use High-Tech Science to Combat Alzheimer’s Disease Challenge
December 14, 2011
 · 
1 min read
Pharm Country
Rick Perry and the Merck & Co., Inc. Gardasil Controversy, Take Two
August 22, 2011
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
March 2, 2026
 · 
19 min read
Press Releases
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 2, 2026
 · 
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
March 2, 2026
 · 
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
March 2, 2026
 · 
19 min read
Press Releases
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
February 26, 2026
 · 
2 min read
Press Releases
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
February 26, 2026
 · 
8 min read
Press Releases
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
February 26, 2026
 · 
19 min read
Press Releases
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 24, 2026
 · 
8 min read
Press Releases
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
 · 
3 min read
Press Releases
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
February 23, 2026
 · 
5 min read
Load More